15 search results for: Bullous Pemphigoid
Beyond Signs and Symptoms: Broadening Treatment Goals in Dermatology
Dr Lawrence Eichenfield explores the broadening of treatment goals for long-term disease control, highlighting the importance of this approach in atopic dermatitis. Drs Culton, Elmariah, and Hawkes expand the discussion to further examine specific management goals unique to each skin disease (bullous pemphigoid, prurigo nodularis, and chronic spontaneous urticaria).
ADVENT at EADV 2025
Join leading dermatologists for educational symposia on atopic dermatitis, bullous pemphigoid, and chronic spontaneous urticaria at the EADV congress in Paris, France.
Time to Act: Reducing the Impact of Uncontrolled Disease Through Early Intervention
Dr Jason Hawkes describes the importance of early intervention for patients with uncontrolled skin diseases and the effectiveness of evidence-based management strategies, sharing a patient case and his clinical insights with chronic spontaneous urticaria. Drs Eichenfield, Elmariah, and Culton join to review the burdens faced by patients with atopic dermatitis, prurigo nodularis, and bullous pemphigoid, respectively.
Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases
Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively.
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.
Decoding the Clinical Puzzle: Navigating Diagnostic Complexity Across Inflammatory Skin Diseases
Dr Sarina Elmariah highlights the clinical challenges in diagnosing inflammatory skin diseases, using prurigo nodularis as a case study. Drs Culton, Eichenfield, and Hawkes then join in to discuss additional challenges and complexities when diagnosing other skin diseases.
ADVENT at EADV 2024
Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.
ADVENT Forum 2025 On Demand page
Watch on-demand expert soundbites recorded at the April 2025 ADVENT Forum in Lisbon, Portugal, featuring dermatology and immunology perspectives on mechanisms and clinical practice. Topics range from disease mechanism to patient care and quality of life, spanning atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
